KIF20A is associated with clinical prognosis and synergistic effect of gemcitabine combined with ferroptosis inducer in lung adenocarcinoma

Gemcitabine (GEM), an antimetabolite that terminates DNA synthesis, is commonly used in the treatment of cancers including lung adenocarcinoma (LUAD). However, downregulation of sensitivity limits the therapeutic effect. Ferroptosis as the new form of regulated cell death has been shown to have grea...

Descripción completa

Detalles Bibliográficos
Autores principales: He, Hua, Liang, Lu, Huang, Jingjing, Jiang, Shiyao, Liu, Yueying, Sun, Xiaoyan, Li, Yi, Cong, Li, Jiang, Yiqun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9549118/
https://www.ncbi.nlm.nih.gov/pubmed/36225575
http://dx.doi.org/10.3389/fphar.2022.1007429

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9549118/
https://www.ncbi.nlm.nih.gov/pubmed/36225575
http://dx.doi.org/10.3389/fphar.2022.1007429

Ejemplares similares